{"id":1383,"date":"2019-01-22T09:32:59","date_gmt":"2019-01-22T09:32:59","guid":{"rendered":"https:\/\/blogs.bmj.com\/spcare\/?p=1383"},"modified":"2019-01-22T09:33:08","modified_gmt":"2019-01-22T09:33:08","slug":"short-cuts-14","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/spcare\/2019\/01\/22\/short-cuts-14\/","title":{"rendered":"Short Cuts"},"content":{"rendered":"<p><strong>Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later<\/strong><\/p>\n<p>Sebastiano Mercadante, Franco Marinangeli, Francesco Masedu, Marco Valenti, Domenico Russo, Laura Ursini, Alessia Massici, and Federica Aielli<br \/>\nJ Pain Symptom Manage. 2018 Dec;56(6):902-907<\/p>\n<p>&nbsp;<\/p>\n<p>This open-label study compared the use of hyoscine butylbromide prophylactically in dying patients with a reduced level of consciousness (n=51) versus giving hyoscine butylbromide to dying patients only once they developed noisy respiratory tract secretions (n=81). Patients were administered 20mg of hyoscine butylbromide as a subcutaneous or intravenously bolus, followed by 60 mg\/24 hours. In patients who were given prophylactic hyoscine butylbromide, 5.9% developed death rattle whilst 60.5% had death rattle in the group who were given hyoscine butylbromide once death rattle was established. There was a significant difference for the onset of death rattle in both groups (median time 12 hours vs 36 hours in the prophylactic group, P=0.0001). Side effects were not reported. The authors suggest that future studies consider a placebo-controlled trial with pre-emptive administration of hyoscine butylbromide may be useful to confirm the results of this exploratory study.<\/p>\n<p>Composed by Elaine Boland.<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later Sebastiano Mercadante, Franco Marinangeli, Francesco Masedu, Marco Valenti, Domenico Russo, Laura Ursini, Alessia Massici, and Federica Aielli J Pain Symptom Manage. 2018 Dec;56(6):902-907 &nbsp; This open-label study compared the use of hyoscine butylbromide prophylactically in dying patients with a reduced level of consciousness [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/spcare\/2019\/01\/22\/short-cuts-14\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":275,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1982],"tags":[],"class_list":["post-1383","post","type-post","status-publish","format-standard","hentry","category-short-cuts"],"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts\/1383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/users\/275"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/comments?post=1383"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts\/1383\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/media?parent=1383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/categories?post=1383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/tags?post=1383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}